What is the safest antibiotic ophthalmic ointment for a newborn infant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safest Antibiotic Eye Drops in Infancy

Erythromycin 0.5% ophthalmic ointment is the safest and only FDA-approved antibiotic for neonatal ocular prophylaxis currently available in the United States. 1

Primary Recommendation

  • Erythromycin 0.5% ophthalmic ointment should be applied as a single application to both eyes of every newborn as soon as possible after delivery, regardless of whether delivery is vaginal or cesarean. 2, 1

  • This medication is specifically designed to prevent sight-threatening gonococcal ophthalmia neonatorum, which develops in approximately 28% of newborns delivered to women with gonorrheal disease and can cause corneal scarring, ocular perforation, and blindness if untreated. 1

  • Single-use tubes or ampules are preferable to multiple-use tubes to minimize contamination risk. 2

Historical Context and Alternative Agents

While older CDC guidelines listed multiple options, the current landscape has changed:

  • Silver nitrate 1% aqueous solution was previously recommended 2 but is no longer commonly used due to higher ocular toxicity compared to erythromycin (significantly more chemical conjunctivitis at 24 hours, P < .001). 3

  • Tetracycline 1% ophthalmic ointment was previously recommended 2 but is no longer available in the United States. 1

  • Povidone-iodine 2.5% has demonstrated superior antibacterial efficacy compared to both erythromycin and silver nitrate in reducing bacterial colony-forming units and species 3, but it is not FDA-approved for this indication in the United States. 1

Important Clinical Considerations

Efficacy Limitations

  • Erythromycin is primarily effective against gonococcal ophthalmia but has less clear efficacy against chlamydial ophthalmia. 2, 1

  • Prophylaxis does not eliminate nasopharyngeal colonization by Chlamydia trachomatis, which may require systemic treatment if infection develops. 1

  • Research evidence suggests that single-dose erythromycin prophylaxis does not significantly reduce the incidence of neonatal chlamydial conjunctivitis compared to no prophylaxis (1.5% vs 1.6%). 4

Legal and Practical Requirements

  • Ocular prophylaxis is required by law in most states, making this a mandatory intervention rather than an optional one. 1

  • If prophylaxis is delayed beyond the delivery room, establish a monitoring system to ensure all infants receive treatment. 2, 1

Systemic Treatment for Active Infection

When treating established gonococcal ophthalmia (not prophylaxis), the approach differs:

  • Ceftriaxone is approved for all gonococcal infections in children, while cefotaxime is approved specifically for gonococcal ophthalmia only. 2

  • Only parenteral cephalosporins are recommended for treating active gonococcal infections in children. 2

Common Pitfalls to Avoid

  • Do not use bacitracin for neonatal ocular prophylaxis—it is not effective. 2

  • Do not skip prophylaxis for cesarean deliveries—all infants require prophylaxis regardless of delivery method. 2, 1

  • Remember that the best prevention strategy is prenatal screening and treatment of pregnant women for N. gonorrhoeae and C. trachomatis, though not all women receive prenatal care. 1

  • Be aware that macrolide resistance is increasing, which may further limit erythromycin's effectiveness against gonococcal infections. 5

Evidence Quality Note

While moderate-certainty evidence suggests prophylaxis probably reduces conjunctivitis of any etiology (RR 0.65,95% CI 0.54-0.78) 6, the evidence for preventing specifically gonococcal or chlamydial conjunctivitis is of very low to low certainty. 6 Despite these limitations, erythromycin 0.5% remains the standard of care due to its safety profile, legal requirements, and lack of superior alternatives currently available in the United States. 1

References

Guideline

Erythromycin Ophthalmic Ointment for Newborns

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Povidone-iodine for ophthalmia neonatorum prophylaxis.

American journal of ophthalmology, 1994

Research

Neonatal ocular prophylaxis in the United States: is it still necessary?

Expert review of anti-infective therapy, 2023

Research

Interventions for preventing ophthalmia neonatorum.

The Cochrane database of systematic reviews, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.